Cargando…
Pioglitazone in diabetic kidney disease: forgotten but not gone
Diabetic kidney disease (DKD) is described in approximately 20–40% of all diabetic patients and is associated with significant cardiovascular and all-cause mortality. The involvement of multiple metabolic, haemodynamic, inflammatory, and tubular pathways in the pathophysiology of DKD generates the n...
Autor principal: | Papaetis, Georgios S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487837/ https://www.ncbi.nlm.nih.gov/pubmed/36158067 http://dx.doi.org/10.5114/amsad/151046 |
Ejemplares similares
-
Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state
por: Papaetis, Georgios S.
Publicado: (2021) -
GLP-1 receptor agonists, SGLT-2 inhibitors, and obstructive sleep apnoea: can new allies face an old enemy?
por: Papaetis, Georgios S.
Publicado: (2023) -
Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns
por: Papaetis, Georgios S., et al.
Publicado: (2015) -
Grief and mourning gone awry: pathway and course of complicated grief
por: Shear, M. Katherine
Publicado: (2012) -
Gone but not Forgotten
por: Parsons, Ryan G., et al.
Publicado: (2011)